Kit for detecting ctDNA and expression of drug-resistant genes related to applicability of tumor chemotherapeutic drugs

A kit for determining ctDNA concentration and a method for determining ctDNA concentration is disclosed, wherein the method comprising dissolving extracted ctDNA in Tris-HCl buffer with pH>7.0 and adding into the buffer 2,7-bis(1-methyl-4-vinylpyridine)-9-ethylcarbazole iodised salt as a molecula...

Full description

Saved in:
Bibliographic Details
Main Authors Gao, Rui, Zhou, Shi, Liang, Ya Ling, Zhuang, Hai, Yu, Wenfeng, Wang, Bi, Zhao, Dai Wei, Huang, Zhi
Format Patent
LanguageEnglish
Published 14.07.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
HETEROCYCLIC COMPOUNDS
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A kit for determining ctDNA concentration and a method for determining ctDNA concentration is disclosed, wherein the method comprising dissolving extracted ctDNA in Tris-HCl buffer with pH>7.0 and adding into the buffer 2,7-bis(1-methyl-4-vinylpyridine)-9-ethylcarbazole iodised salt as a molecular probe, calculating the concentration of ctDNA in the solution by measuring the Fluorescence intensity of the solution. It has extremely high sensitivity in the determination of 0 μg/ml˜50 μg/ml ctDNA solution.
Bibliography:Application Number: US201815944725